Twist Bioscience Corporation Shareholders' Equity
Twist Bioscience Corporation (TWST) had Shareholders' Equity of $445.74 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-03
- 2026-06-30: Stockholders' Equity Attributable to Parent $445.74M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $455.09M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $456.10M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $472.96M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $445.74M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $455.09M 10-Q · filed 2026-08-03 |
| 2025-12-31 | $456.10M 10-Q · filed 2026-05-04 |
| 2025-09-30 | $472.96M 10-Q · filed 2026-08-03 |
| 2025-06-30 | $478.20M 10-Q · filed 2026-08-03 |
| 2025-03-31 | $440.11M 10-Q · filed 2026-08-03 |
| 2024-12-31 | $455.94M 10-Q · filed 2026-05-04 |
| 2024-09-30 | $472.69M 10-Q · filed 2026-08-03 |
| 2024-06-30 | $491.14M 10-Q · filed 2025-08-04 |
| 2024-03-31 | $560.13M 10-Q · filed 2025-08-04 |
| 2023-12-31 | $590.04M 10-Q · filed 2025-05-05 |
| 2023-09-30 | $623.43M 10-K · filed 2025-11-17 |
| 2023-06-30 | $657.55M 10-Q · filed 2024-08-02 |
| 2023-03-31 | $703.93M 10-Q · filed 2024-08-02 |
| 2022-12-31 | $746.33M 10-Q · filed 2024-05-02 |
| 2022-09-30 | $789.38M 10-K · filed 2025-11-17 |
| 2022-06-30 | $820.68M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $863.36M 10-Q · filed 2023-08-07 |
| 2021-12-31 | $626.18M 10-Q · filed 2023-05-08 |
| 2021-09-30 | $580.82M 10-K · filed 2024-11-18 |
| 2021-06-30 | $610.45M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $614.18M 10-Q · filed 2022-08-08 |
| 2020-12-31 | $637.95M 10-Q · filed 2022-05-06 |
| 2020-09-30 | $336.26M 10-K · filed 2023-11-21 |
| 2020-06-30 | $348.95M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $264.20M 10-Q · filed 2021-08-09 |
| 2019-12-31 | $103.08M 10-Q · filed 2021-05-07 |
| 2019-09-30 | $152.08M 10-K/A · filed 2023-06-05 |
| 2019-06-30 | $176.00M 10-Q · filed 2020-08-12 |
| 2019-03-31 | $115.48M 10-Q · filed 2020-08-12 |
| 2018-12-31 | $138.60M 10-Q · filed 2020-05-13 |
| 2018-09-30 | -$201.42M 10-K · filed 2021-11-23 |
| 2018-06-30 | -$182.76M 10-Q · filed 2019-08-09 |
| 2018-03-31 | -$165.72M 10-Q · filed 2019-08-09 |
| 2017-12-31 | -$149.70M 10-Q · filed 2019-05-02 |
| 2017-09-30 | -$133.36M 10-K · filed 2020-11-27 |
| 2016-09-30 | -$76.61M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |